A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL919 in Healthy Participants
- Conditions
- AlzheimersAlzheimer's Disease10012303
- Registration Number
- NL-OMON51440
- Lead Sponsor
- Denali Therapeutics Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 80
Healthy male participants and healthy female participants of non childbearing
potential aged between 18 and 55 years, inclusive, with a body mass index (BMI)
between 18.5 and 32 kg/m2, inclusive
Women of childbearing potential will be excluded in this study because
reproductive toxicity studies have not yet been performed. Also, participants
with any history of clinically significant neurological, psychiatric, endocrine
(including diabetes mellitus), pulmonary, cardiovascular, gastrointestinal,
hepatic, pancreatic, renal, metabolic, hematologic, immunologic, or allergic
disease, or other major disorders.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.